The trial is a global phase I/II, open-label study that will evaluate the recommended dose for safety and immunogenicity of the novel anti-ROR1 antibody-drug conjugate in patients with advanced solid tumors. The initial results from the study are expected in 2021.

NBE-002 was developed on the company's immunestimulatory antibody-drug conjugate (iADC) platform, which creates highly potent, immunostimulatory antibody-drug conjugates with a novel anthracycline payload. The lead candidate, NBE-002, has been demonstrated as safe and tolerable during preclinical development. It targets ROR1, a cell-surface protein that is expressed in malignant tissues across a broad variety of cancer types, including solid tumors.

Exelixis enters collaborations for antibody drug conjugates
Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates...